Compare Lam Research Corporation (LRCX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Repligen Corporation Common Stock — how do they compare? Lam Research Corporation trades at $279.29 (market cap $359.06B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Lam Research Corporation is far larger — about 31.7× Repligen Corporation Common Stock's market cap, and Lam Research Corporation pays a 0.46% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 61 Days and Repligen Corporation Common Stock for 0 Days on average.
| LRCX | RGEN | |
|---|---|---|
Market Cap | $359.06B | $11.31B |
Volume | 10,336,294 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $433.33 | $194.57 |
52-Week Low | $139.59 | $102.87 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $357.21B | $11.20B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $301.11, down 2.73% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $18.44B in 2025, with a net income margin of 31.27% and robust cash flow from operations of $6.17B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $375.68.
LRCX presents a compelling long-term opportunity driven by AI-driven semiconductor equipment demand, though near-term technical weakness and high valuation multiples pose risks. The company's strategic positioning in advanced chip manufacturing supports growth, but investors should monitor execution against earnings expectations and competitive dynamics in the semiconductor equipment sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
